Headlines

NYSE:JNJ

Watch List : Johnson & Johnson (NYSE:JNJ), Taiwan Semiconductor Manufacturing Company Limited (NYSE:TSM), Magnetek Inc. (NASDAQ:MAG), Employers Holdings, Inc. (NYSE:EIG), Hornbeck Offshore Services, Inc. (NYSE:HOS)

Jayne Crisman02 mins

Johnson & Johnson (NYSE:JNJ) shares are higher by 0.45% to $97.44 after the company reported third quarter net income of $4.7 billion, or $1.66 per diluted share, compared to $2.9 billion, or $1.04 per diluted share, for the same period a year ago. Johnson & Johnson (NYSE:JNJ) belongs to Healthcare sector. Its net profit margin…

Read More

Trader’s Recap : Office Depot, Inc. (NASDAQ:ODP), Zogenix, Inc. (NASDAQ:ZGNX), Johnson & Johnson (NYSE:JNJ), Intel Corporation (NASDAQ:INTC), Verizon Communications Inc. (NYSE:VZ)

Colin Pettis02 mins

The 2013 merger of Office Depot, Inc. (NASDAQ:ODP) and OfficeMax means the end of one’s presence in Jackson. Office Depot, 1510 N. West Ave., will close Nov. 15. The location is advertising merchandise being 50 percent off as part of a “moving” sale. Office Depot, Inc. (NASDAQ:ODP) belongs to Services sector. Its net profit margin…

Read More

Investors Watch List : Johnson & Johnson (NYSE:JNJ), VIVUS Inc. (NASDAQ:VVUS), SVB Financial Group (NASDAQ:SIVB), AT&T, Inc. (NYSE:T), Modine Manufacturing Company (NYSE:MOD)

Chris Lewis02 mins

Johnson & Johnson (NYSE:JNJ) said on Tuesday that it would pay $1.75 billion in cash for Alios BioPharma, a private biotechnology company that is working on treatments for viral diseases. Johnson & Johnson (NYSE:JNJ) belongs to Healthcare sector. Its net profit margin is 21.20% and weekly performance is -3.03%. On last trading day company shares…

Read More

Active Watch List : Johnson & Johnson (NYSE:JNJ), Applied Materials, Inc. (NASDAQ:AMAT), PTC Therapeutics, Inc. (NASDAQ:PTCT), DIRECTV (NASDAQ:DTV), Phillips 66 Partners (NYSE:PSXP)

Chris Lewis02 mins

Johnson & Johnson (NYSE:JNJ) announced a definitive agreement to acquire Alios BioPharma, Inc., a privately held clinical stage biopharmaceutical company focused on developing therapies for viral diseases, for approximately $1.75 billion in cash. The acquisition will include Alios BioPharma’s portfolio of potential therapeutics for viral infections including compound AL-8176, an orally administered antiviral therapy currently…

Read More
Home